Plain-English translation of NCT06887192 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called to see if it can help reduce hallucinations (seeing or hearing things that aren't there) and delusions (believing things that aren't true) in people who have Alzheimer's disease. About 300 people will participate, and half will receive the medication while the other half will receive a placebo (a dummy pill with no active ingredient). Researchers will measure how well the medication works compared to placebo over the course of the study.
Some people with Alzheimer's disease experience disturbing hallucinations and delusions that can make them scared or confused, and these symptoms can be very hard on both the patient and their caregivers. Currently, there aren't many treatments specifically designed for these symptoms in Alzheimer's disease, so this study is testing whether this new medication could offer patients another option.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either the new medication or a placebo, and neither you nor the researchers will know which one you're getting until the study ends. You will visit the research clinic regularly so the study team can check on your symptoms, measure how you're doing, and watch for any side effects. Throughout the study, your care partner will help report on your symptoms and make sure you're taking the medication or placebo as directed.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States